glp-1 news today october 2025 obesity drug A nice article in The Hindu highlights the GLP-1s: The Swiss Army Knife

100% 30 Day Money Back Guarantee Secure Payment Naturopath About Amanda Amanda has been active in the natural health industry for over 15 years

The proportion of male neonates was 43.24%, possibly influenced by the small sample size in this study (see Table 4 )

In recent years, an increasing number of small molecules have been identified that modulate ferroptosis sensitivity through the GPX4GSH axis

Phase 3 results are needed No cardiovascular outcomes data available The biased signaling mechanism, while promising, needs long-term validation Exact molecular structure has not been publicly disclosed Phase 3 trials are planned but not yet enrolled Effects of CT-388, a once-weekly signaling-biased dual GLP-1/GIP receptor agonist, on weight loss and glycemic control in preclinical models and participants with obesity , published in Cell Metabolism (Roche/Genentech/Carmot Therapeutics investigators, 2025